Blood pressure and end-stage renal disease in men

New England Journal of Medicine

Volumn 334, Issue 1, 1996, Pages 13-18

  Klag, Michael J ^a,f,g   Whelton, Paul K ^a   Randall, Bryan L ^b   Neaton, James D ^b   Brancati, Frederick L ^a   Ford, Charles E ^c   Shulman, Neil B ^d   Stamler, Jeremiah ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g AMERICAN HEART ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UNITED STATES; URINARY EXCRETION;

ADULT; BLOOD PRESSURE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030034592     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199601043340103     Document Type: Article

References (41)

1. Renal Data System. USRDS 1994 annual data report. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, 1994. (NIH publication no. 94-3176.)
2. Whelton PK, Klag MI. Hypertension as a risk factor for renal disease, review of clinical and epideimological evidence Hypertension 1989,13:Suppl I.I19-I27
3. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial, risk factor changes and mortality results JAMA 1982,248:1465-77.
4. The Multiple Risk Factor Intervention Trial Research Group. Statistical design considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis 1977;30.261-75.
5. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE Jr. The Multiple Risk Factor Intervention Trial (MRFIT) II. the development of the protocol. Prev Med 1981;10:402-25.
6. Neaton JD, Grimm RH Jr, Cutler JA Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). Control Clin Trials 1987; 8:Suppl:41S-53S.
7. Dischinger P, DuChene AG. Quality control aspects of blood pressure measurements in the Multiple Risk Factor Intervention Trial Control Clin Trials 1986,7:Suppl:137S-157S.
8. National Heart and Lung Institute. Manual of laboratory operations: Lipid Research Clinics Program. Washington, D C.: Government Printing Office. 1974. (DHEW publication no. (NIH) 75-628.)
9. Health Care Financing Administration. Research report: end stage renal disease, 1985 Washington, D.C : Government Printing Office, 1987. (HCFA publication no. 03274.)
10. Wentworth DN, Neaton JD, Rasmussen WL An evaluation of the Social Security Administration master beneficiary record file and the National Death Index in the ascertainment of vital status. Am J Public Health 1983;73: 1270-4.
11. Department of Health and Human Services. The international classification of diseases, 9th rev., clinical modification: ICD-9-CM. Vol. I. Diseases, tabular list. Washington, D.C., Government Printing Office, 1980. (DHHS publication no. (PHS) 80-1260.)
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972,34:187-202.
14. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993,153: 598-615.
15. Stamler J, Stamler R, Neaton JD Blood pressure, systolic and diastolic, and cardiovascular risks: U.S population data Arch Intern Med 1993;153:598-615.
16. Neaton JD, Wentworth D Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
17. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993,16.434-44.
18. Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q J Med 1958;27:117-53.
19. Perera GA. Hypertensive vascular disease, description and natural history. J Chronic Dis 1955;1:33-42.
20. Mroczek WJ, Davidov M, Gavrilovich L, Finnerty FA Jr. The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 1969;40:893-904.
21. Mamdani BH, Lim VS, Mahurkar SD, Katz AI, Dunea G. Recovery from prolonged renal failure in patients with accelerated hypertension. N Engl J Med 1974;291:1343-4.
22. Whittle JC, Whelton PK, Seidler AJ, Klag MJ Does racial variation in risk factors explain black-white differences in the incidence of hypertensive endstage renal disease? Arch Intern Med 1991;151:1359-64.
23. Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year endstage renal disease in hypertensive patients. Hypertension 1995;25.587-94.
24. Shulman NB, Ford CE, Hall DW, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program Hypertension 1989,13: Suppl I.I80-I93.
25. Pernerger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine: results from the "Clue" Study and the ARIC Study. JAMA 1993;269:488-93.
26. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990,150:2073-6.
27. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Protemuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus - a 14-year follow-up report on 195 patients. Arch Intern Med 1992;152:1225-9.
28. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989;320.684-8.
29. Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and type U diabetes mellitus. Am J Kidney Dis 1989;13:485-93.
30. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA 1992;268.3085-91.
31. Klahr S, Schreiner G, Ichikawa T. The progression of renal disease. N Engl J Med 1988;318.1657-66.
32. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis Hypertension 1989;13:766-72.
33. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.
34. Brazy PC, Fitzwilliam JF Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990;37.1113-9.
35. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-8.
36. Bergstrom J, Alvestrand A, Bucht M, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986;25:1-6
37. Perneger TV, Whelton PK, Klag MJ, Rossiter KA Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol 1995; 141:10-5.
38. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus Ann Intern Med 1994;121:912-8.
39. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-74.
40. National Heart, Lung, and Blood Institute. Report on the Task Force on Research in Epidemiology and Prevention of Cardiovascular Diseases. Bethesda, Md : Department of Health and Human Services, 1994.
41. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 1993;153:186-208.